April 2012 in “The Journal of Urology” Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
4 citations
,
May 2013 in “Canadian Urological Association Journal” Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
49 citations
,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
7 citations
,
October 2017 in “The Prostate” Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.
2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
Finasteride significantly reduces the risk of prostate cancer.
November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.
1 citations
,
April 2008 in “Progrès en Urologie” Finasteride shows promise for preventing prostate cancer, but more research is needed.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
12 citations
,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
Finasteride significantly reduces prostate cancer risk.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
7 citations
,
July 2019 in “Scientific Reports” Finasteride helps reduce heart enlargement in heart failure patients.
20 citations
,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
33 citations
,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
20 citations
,
June 2015 in “Hormone Molecular Biology and Clinical Investigation” Finasteride worsens erectile dysfunction and lowers testosterone in men with enlarged prostates, unlike tamsulosin.
April 2023 in “Research Square (Research Square)” Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.